美国诺瓦瓦克斯Novavax, Inc.
Novavax公司是致力于新型的、高效的传染病疫苗临床阶段研究的前沿性企业，这些新型疫苗比现有的疫苗更具安全性和有效性。通过公司的病毒样颗粒载体专利（VLP）和Novasome®辅助技术，我们正在研发对抗H5N1型禽流感病毒、季节性流感和其它病毒性传染病的疫苗。Novavax公司的微粒疫苗能更好地匹配因为缺乏遗传性抗性导致疾病的致病病毒，以达到在更低的剂量时，就可以为机体提供强大的潜在免疫保护作用。同时，专用的便携式生产系统，可以快速生产大量疫苗， 这一独一无二的优越条件，可以更好地满足全球公共卫生的需要。

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based potent, recombinant vaccines utilizing a new and efficient manufacturing approach.
Our world-class scientific team is using virus-like particle (VLP) technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. Our team has created vaccines designed to protect against various circulating strains of avian influenza as well as seasonal flu, Respiratory Syncytial Virus (RSV) and Varicella Zoster Virus (VZV). We have validated our approach in animals and are now in clinical testing with our pandemic and seasonal influenza vaccine.

Our vision is a holistic approach to controlling the spread of disease. Using a unique portable manufacturing system that allows for rapid mass production, our long-term goal is to be able to rapidly deliver a customized vaccine in the midst of a pandemic.

Novavax plans to apply its particle-based vaccine approach to other viral diseases beyond influenza.